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CHARACTERIZATION AND FUNCTIONAL ANALYSIS OF THE P2Y2R GENE 
PROMOTER 
 
Nishant Jain 
Thesis Advisors: Dr. Cheikh Seye and Dr. Gary A. Weisman 
ABSTRACT 
 
Extracellular nucleotides can bind to the P2Y2R and modulate proliferation and migration 
of smooth muscle cells, which is known to be involved in intimal hyperplasia that 
accompanies atherosclerosis and post-angioplasty restenosis. Moreover, the P2Y2R is up-
regulated in vascular smooth muscle cells and endothelial cells in response to tissue 
injury. These findings suggest that the P2Y2R is a potential target for the pharmacological 
control of progression of atherosclerosis and post-angioplasty restenosis. However, the 
mechanisms governing P2Y2R up-regulation remain unknown.  
In this study, we have cloned a 2071 bp 5’-flanking region of the P2Y2R gene in a 
reporter vector and carried out a serial deletion analysis. The deletion of a 175 bp region 
completely abolished promoter function and results further indicate that the P2Y2R gene 
promoter uses an array of positive and negative response elements in the regulation of 
gene expression. Furthermore, other results show that the cytokine IL-1β may be 
involved in down-regulation of P2Y2R activity in human coronary artery endothelial 
cells.  Further studies will potentially lead to the identification of novel pathways 
involved in the regulation of P2Y2R gene expression, information that might be useful to 
suppress neointimal hyperplasia in atherosclerosis and the restenosis of angioplasty.  
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CHAPTER 1: INTRODUCTION 
 
 
 
I. Historical Perspective  
The seminal work of Drury and Szent-Gyorgi in 1929 described the involvement 
of extracellular nucleotides and nucleosides in potent biological actions in mammalian 
heart and blood vessels; they showed that intravenous injection of purines into whole 
animals induced a decrease in heart rate and arterial blood pressure, dilation of coronary 
blood vessels and inhibition of intestinal movements. Furthermore, Holton suggested a 
role for adenosine 5’-triphosphate (ATP) as a transmitter in the nervous system by using 
the firefly luciferase assay to show that ATP is released during antidromic stimulation of 
sensory nerves in sufficient quantities to produce vasodilatation of rabbit ear arteries 1,2. 
Eleven years later, the neurotransmitter-like activity of ATP was demonstrated in non-
adrenergic, non-cholinergic nerves supplying the gut 3. This led to the controversial 
proposal of the “purinergic-neurotransmission” hypothesis which stated that the 
intracellular metabolite ATP or a related nucleotide can act as a neurotransmitter when 
released from nerves in the gut and bladder 4. Although the concept of extracellular 
nucleotides as signaling molecules met with resistance initially, it has now been firmly 
established that ATP acts as a co-transmitter along with classical neurotransmitters (e.g., 
acetylcholine) in both the peripheral and the central nervous systems, and that purine 
nucleotides are powerful extracellular messengers in non-neuronal cells, including 
exocrine, endocrine, secretory, endothelial, bone, immune and inflammatory cells 5.  
Early investigations into the effects of adenosine were particularly made on heart and 
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vasculature 2,6.  Initial studies on the effects of extracellular UTP also focused on its 
cardiovascular effects 2.  
II. Extracellular Release of Nucleotides 
Earlier, little was known about the sources and release of nucleotides in 
mammalian cells 7. The development of sensitive assays that utilized a cell-surface 
targeted luciferase as an ATP sensor enabled the more accurate measurement of the 
concentrations of extracellular nucleotides in the pericellular environment of cells 8. 
These methods have shown that extracellular nucleotides are released constitutively by 
many cell types under unstimulated conditions. Stimuli such as stress or mechanical 
stimulus can lead to increased levels of extracellular nucleotides. It has been postulated 
that cells maintain a steady-state equilibrium between release and ecto-metabolism of 
extracellular nucleotides 9. 
ATP and adenosine 5’-diphosphate (ADP) are released from sympathetic nerves, 
activated platelets, erythrocytes, cardiac tissue, mast cells, endothelial cells, and smooth 
muscle cells 10-12. The main source of intraluminal ATP is likely to be endothelial cells, 
and its release can be measured during conditions such as changes in the rate of blood 
flow and hypoxia in amounts sufficient to activate endothelial cell G protein-coupled P2Y 
purinoceptors 13.  It also has been shown that ATP is released from vesicles in urothelial 
and endothelial cells in the ureter leading to acute inflammation 14. The effects of ATP 
are often counteracted by its degradation product adenosine. Levels of the pyrimidine 
nucleotide uridine 5’-triphosphate (UTP) increase in human plasma in response to 
alterations in blood flow 15,16 and animal studies have shown that UTP release occurs in 
heart during cardiac ischemia, most likely from cardiomyocytes and to a lesser extent 
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from red blood cells and endothelial cells 17. Several lytic and non-lytic mechanisms for 
the release of UTP and ATP have been proposed. Tissue damage and cell lysis can cause 
an increase in extracellular nucleotide levels.  Nucleotide release mechanisms associated 
with excitable and secretory tissues include vesicular exocytosis in ureter epithelium 18 
and exocytotic granule release 19. Other mechanisms include transport by ATP-binding 
cassette (ABC) proteins, stretch-activated channels and voltage-activated channels 
(which are still controversial)  14,20. Apart from these mechanisms, additional ATP 
transporters have been hypothesized to exist in murine cells 21. 
The levels of extracellular nucleotides depend both on release mechanisms and 
the activities of cell-surface enzymes that metabolize nucleotides, such as soluble and 
membrane-bound ecto-nucleotidases that are expressed in most cell types 22. A variety of 
different ecto-enzymes can participate in degradation and interconversion of extracellular 
nucleotides. These include the E-NTPDase (ecto-nucleoside 5´-triphosphate 
diphosphohydrolase; previously known as ecto-apyrase, NTPase or E-ATPase) family 
that hydrolyzes nucleoside 5´-triphosphates to diphosphates and then to monophosphates, 
the E-NPP (ecto-nucleotide pyrophosphatase/phosphodiesterase) family that hydrolyzes 
phosphodiester bonds, the ecto-5´-nucleotidase and alkaline phosphatase families that 
hydrolyze terminal phosphates of nucleoside 5´-monophosphates to yield the 
corresponding nucleoside, and the nucleotide converting enzyme ecto-NDPK (ecto-
nucleoside diphosphokinase) and adenylate kinase that phosphorylate adenosine 5´-
monophosphate 22.  E-NPP isoenzymes can hydrolyze either purine or pyrimidine 
nucleotides, as well as dinucleotides and uridine 5’-diphosphate-conjugated sugars (UDP-
sugars). E-NPP can hydrolyze ATP into AMP and pyrophosphate (PPi); 3’, 5’-cyclic 
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AMP (cAMP) into AMP; ADP into AMP and inorganic phosphate (Pi); and NAD+ 
(nicotinamide dinucleotide) into AMP and nicotinamide mononucleotide.  Ecto 5’-
nucleotidase is the major enzyme involved in the formation of adenosine in the 
extracellular space.  Ecto-NDPK catalyzes the reversible transphosphorylation of 
nucleoside 5’-diphosphates into nucleoside 5’-triphosphates such as ATP + UDP to ADP 
+ UTP 23-28. Alkaline phosphatase activity alone can catalyze the complete sequential 
hydrolysis of a nucleoside 5’-triphosphate to the corresponding nucleoside 22. Alkaline 
phosphatase also can hydrolyze PPi 29,30.   
III. Classification of P2 Receptors 
Extracellular nucleotides and their metabolites act through two classes of 
receptors termed P1 receptors, whose ligand is adenosine, and P2 receptors, whose 
ligands include ATP, ADP, UTP, UDP and UDP-glucose. There are two different 
categories of P2 receptors: G protein-coupled P2Y receptors, and P2X ligand-gated ion 
channels (Table I). Eight P2Y receptor subtypes and seven P2X receptor subtypes have 
been cloned. The 8 human P2Y receptors can be grouped into two structurally distinct 
subfamiles: P2Y1, P2Y2, P2Y4, P2Y6 and P2Y11 in one group that couples to 
phospholipase C, whereas P2Y12, P2Y13 and P2Y14 belong to a group that couples to 
adenylate cyclase.  In the case of P2Y11, two signaling pathways can be activated, 
adenylyl cyclase as well as phospholipase C  31.  Seven P2X receptor subunits (P2X1-7) 
have been identified, and these subunits can form a variety of homo- and heterotrimeric 
channels. All of these P2 receptors have been characterized pharmacologically and 
accepted as valid members of the P2 receptor family 32,33 .  
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Table 1: P2 Receptors: Agonist Potency and Signal Transduction Mechanisms.  
 
Receptor Subtype  Rank Order of Agonist Potency Signal Transduction
    P2Y1 2-MeSADP > ADP > 2-MeSATP > ATP PLC /IP3/Ca2+ 
    P2Y2 UTP = ATP > Ap4A > ATPγS PLC /IP3/Ca2+ 
    P2Y4 UTP > UTPγS >> ATP, UDP PLC /IP3/Ca2+ 
    P2Y6 UDP = 5-Br-UDP >> UTP > 2-MeSADP PLC /IP3/Ca2+ 
    P2Y11 ATPγS = BzATP > ATP > 2-MeSATP PLC /IP3/Ca2+ 
    P2Y12 2MeSATP = 2MeSADP > ADP Adenylate Cyclase 
    P2Y13 2MeSATP = 2MeSADP > ADP > ATP Adenylate Cyclase 
    P2Y14 UDP-glucose > UDP-galactose  Adenylate Cyclase 
 
Receptor Subtype  Rank Order of Agonist Potency Signal Transduction 
   P2X1 2-MeSATP > ATP > , -meATP INa+/K+/Ca2+ 
   P2X2 2-MeSATP > ATP, , -meATP inactive INa+/K+ 
   P2X3 2-MeSATP > ATP > , -meATP INa+/K+/Ca2+ 
   P2X4 ATP > 2-MeSATP >> , -meATP INa+/K+ 
   P2X5 ATP > 2-MeSATP > ADP INa+/K+/Ca2+ 
   P2X6 ATP > 2-MeSATP > ADP INa+/K+/Ca2+ 
   P2X7 BzATP > ATP > 2-MeSATP > ADP INa+/K+, pore formation
 
Abbreviations: 2MeSADP , 2-methylthio-ADP; 2MeSATP, 2-methylthio-ATP; ADP, adenosine 5'-
diphosphate; ATP , adenosine 5' - triphosphate; ATPγS, adenosine 5'- triphosphate gamma thiol; BzATP, 2' 
and 3'-O-(4-benzoylbenzoyl)-ATP; , -meATP, , -methylene adenosine 5'- triphosphate; UDP, uridine 
5'-diphosphate; UTP , uridine  5'- triphosphate; PLC,  Phospholipase C; IP3, inositol triphosphate; I , ion 
channel current 
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IV. P2 Receptors in Vascular Cells 
          The normal arterial wall consists of three layers: the intima, media and adventitia. The 
single layer of endothelial cells facing the vascular lumen is a very important component of 
the blood vessel wall in terms of releasing both vasodilators such as nitric oxide (NO) and 
prostacyclin (PGI2), and vasoconstrictors like thromboxane A2 and endothelin. ATP and 
ADP are components of blood-borne elements, such as platelets and erythrocytes, and can 
also be released from endothelial cells and smooth muscle cells  10. The vascular response 
elicited by these purine nucleotides depends on several factors including the nature of the P2 
receptor subtype involved and its location in relation to structural components in the vascular 
wall 34. Endothelium-dependent vasorelaxation is due to the release of prostacyclin and NO 
by the nucleotide-induced activation of P2Y2 as well as P2Y1 receptors 34. The principal P2Y 
receptor subtypes that have been functionally characterized in endothelial cells are P2Y1 and 
P2Y2, but mRNAs for P2Y4 and P2Y6 receptors have also been detected 35. In smooth muscle 
cells, however, activation of the P2Y2R plays a role in vasoconstriction 36,37. P2 receptor 
subtypes in different cell types that make up a blood vessel wall can have opposing effects, 
such as endothelial-mediated vasodilatation or smooth muscle-mediated vasoconstriction 34. 
             Activation of P2Y2 receptors also causes proliferation and migration of vascular 
smooth muscle cells 38-40. P2Y1 receptors are expressed in smooth muscle cells (SMCs) of a 
number of blood vessel types, and like their endothelial cell (EC) counterparts, mediate 
vasodilatation 2. P2Y2 receptors in SMCs mediate the induction of immediate-early and 
delayed-early cell cycle-dependent genes, consistent with a role for these receptors in 
vascular proliferation of SMCs 41,42 . A recent study in rat aortic SMCs demonstrated that the 
P2Y2R is the predominant functional receptor that responds to ATP and UTP 43. The P2Y6 
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receptor is expressed in human cerebral arteries, and mediates vasoconstriction when 
activated by UDP/UTP 44 similar to results with rat pulmonary and mesenteric arteries 45,46. 
Moreover, P2X1 receptor knock-out mice were used to demonstrate that the P2Y6 receptor is 
the prominent P2 receptor that promotes a contractile response in mesenteric arterial trees 47. 
The presence of P2Y4 and P2Y6 receptors has been reported in rat aortic SMCs 41. Major 
blood vessels consist of connective tissue and fibroblasts in the outermost layer. A recent 
study showed that fibroblasts can migrate into the neointima (i.e., the proliferating smooth 
muscle layer of the subendothelial region of blood vessels), suggesting their possible 
involvement in the development of vascular diseases such as atherosclerosis and restenosis 
after angioplasty 48. Human and rat fibroblasts are known to express P2Y1, P2Y2 and P2Y4 
receptors 32, suggesting a role for these receptors in fibroblast activation.  
           P2X receptor subtypes also have been reported in human saphenous vein SMCs, 
including P2X1, P2X2, P2X4 and P2X7 receptors 49. Human  and rat fibroblasts are known to 
express P2X3, P2X4, and P2X7 receptors 32. 
V. Pharmacology and Signal Transduction of P2Y Receptors  
P2Y receptors are found in a wide range of tissue types (Table 2). P2Y receptors 
serve multiple functions in their host cells, working through two major pathways: 1) 
activation of intracellular signaling cascades, via the catalytic G protein α subunit; and 2) 
modulation of membrane ion channel activities, via regulatory G protein βγ subunits 
ralevic 2. Also, a third less well understood pathway may involve the physical interaction 
of P2Y receptors with membrane proteins in their close proximity.  
 P2Y2 receptors have been reported to couple to G proteins including pertussis 
toxin-sensitive Go, pertussis toxin-insensitive Gq/11, and Gi protein 50-53. Activated P2Y2 
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receptors interact with heterotrimeric G proteins and cause GTP/GDP exchange in Gα 
subunits and dissociation of GTP-Gα from Gβγ subunits. Dissociated GTP-Gα subunits 
activate phospholipase C (PLC), which hydrolyzes phosphatidylinositol-4,5-bisphosphate 
(PIP2) into the second messengers inositol-1,4,5-trisphosphate (IP3) and diacylglycerol 
(DAG). IP3 causes Ca2+ release from endoplasmic reticulum into the cytoplasm. Ca2+ and 
DAG activate a variety of downstream pathways including protein kinase C (PKC) and 
mitogen-activated protein (MAP) kinases 54 ,55-57. 
The specific downstream signal transduction pathway involved in P2Y receptor 
activation depends not only on the P2Y receptor subtype but also on the cell type 
expressing the receptor 2. In endothelial cells, P2Y2 receptor-mediated calcium 
mobilization causes phospholipase A2 (PLA2) activation, which leads to the release of 
prostacyclin, and the activation of nitric oxide synthase that leads to the release of NO 
53,58. As with P2Y1 receptors, protein tyrosine phosphorylation and MAP kinase activation 
seem to be a consequence of P2Y2R activation in endothelial cells 59,60. This occurs 
subsequent to activation of PKC and does not involve IP3 or elevation of cytosolic Ca2+ 
levels 60. Stimulation of the P2Y2R in endothelial cells is known to activate a variety of 
signaling molecules including the mitogen- and stress-activated protein kinases ERK1/2 
(extracellular-signal regulated kinases 1/2), p38, and c-Jun NH2-terminal kinase, and the 
small GTPase RhoA 61,62.  More than one subtype of P2Y receptor can regulate responses 
in endothelial cells, and endothelial cells derived from different vascular beds may 
express different combinations of receptors 63. In vascular smooth muscle cells, activation 
of P2Y2 receptors causes phosphatidylinositol 3-kinase (PI3K)-independent activation of 
ERK1/2 and proliferation of smooth muscle cells 39. 
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Src homology domain 3 (SH3) binding sites in the P2Y2 nucleotide receptor 
(P2Y2R) interact with Src or PI3K and regulate the activities of Src, Pyk2, and growth 
factor receptors 62. The integrin binding sequence arginine-glycine-aspartic acid (RGD) 
in the P2Y2R interacts with αvβ3 integrins and is required for activation of focal adhesion 
kinase (FAK) and ERK1/2 52.  The RGD domain in P2Y2R is required for nucleotide-
induced activation of Go- but not Gq-mediated intracellular calcium mobilization 52. More 
recently, Liao Zhongji (unpublished data) has shown that P2Y2R interaction with αv 
integrins is required for it to access and activate G12.  
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Table 2 : Tissue Distribution of P2Y Receptors  
(modified from von Kügelgen et al., 2000 and Burnstock and Knight , 2004) 
 
 
Subtypes expressed in human 
tissues 
Tissue distribution 
  P2Y1 Platelets, heart, skeletal muscle, neuronal tissue, 
digestive tract 
  P2Y2 Lung, heart, skeletal muscle, spleen, kidney, aorta 
  P2Y4 Placenta, lung, vascular smooth muscle 
  P2Y6 Lung, heart, aorta, spleen, placenta, thymus, intestine, 
brain 
  P2Y11 Spleen, intestine, immunocytes 
  P2Y12 Platelets, glial cells 
  P2Y13 Spleen, brain, lymph nodes, bone marrow 
  P2Y14 Placenta, adipose tissue, stomach, intestine, discrete 
brain regions 
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VI. Role of  P2 Receptors in the Vasculature 
 Along with mitogenic effects, nucleotides can be involved in vascular inflammation 
in the following ways: 
1) by increasing expression of adhesion and chemoattractant molecules thus facilitating 
adherence of monocytes to vascular cells 64; 
2) by mediating the secretion of pro-inflammatory cytokines 35 by monocytes or 
macrophages via activation of  P2X7  receptors 65 ; and  
3) by initiating smooth muscle cell migration 61. 
             Involvement of nucleotides in the above processes has been demonstrated by in 
vitro and in vivo studies in endothelial and smooth muscle cells 61,66.  Nucleotides cause 
smooth muscle cell migration via an increase in the expression of osteopontin 61. 
Nucleotides also increase expression of Monocyte Chemoattractant Protein-1 (MCP-1) in  
arterial SMCs 41. Another significant finding is the demonstration that stimulation of P2 
receptors can increase release of the cytokines IL-1β, IL-1α, IL-8 and TNF-α 65. UTP and 
ATP also can increase expression of the monocyte adherence protein, vascular cell 
adhesion molecule-1 (VCAM-1) via activation of P2Y2 receptors 64. Furthermore, ATP 
and UTP have been shown to induce cell-cell adhesion in a human monocyte/macrophage 
lineage and neutrophil adherence to human endothelial cell monolayers 66,67. In vivo 
studies by Seye and colleagues have shown that local UTP delivery to collared rabbit 
carotid arteries can induce accumulation of macrophages in the intima 68. Thus, 
involvement of P2Y2 receptors in leukocyte infiltration and migration suggests that this 
receptor can be targeted in therapies directed at reducing vascular inflammation and 
atherosclerotic lesion development 69. 
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Smooth Muscle Cell Proliferation 
P2 receptors are involved in nucleotide-induced vascular smooth muscle cell 
proliferation, which is a hallmark of vascular diseases such as atherosclerosis and 
restenosis following angioplasty 42,69. Acute responses to nucleotides are mediated by 
both P2X and P2Y receptors, whereas chronic responses are mostly mediated by P2Y 
receptors 69. Various cell culture studies have shown that increases in DNA synthesis and 
the expression of protein markers of cell proliferation occur in vascular smooth muscle 
cells under the influence of nucleotides 70,71. Both P2Y2 and P2Y4 receptors have been 
associated with proliferative responses in vascular smooth muscle cells 72,73. P2Y6 
receptors have also been associated with SMC proliferation in rat aorta 74. 
Smooth Muscle Cell Migration 
Extracellular nucleotides serve as directional cues for rat aortic SMC migration 61. 
Several P2Y receptor subtypes could be involved in nucleotide-mediated SMC 
migration, although in rat aortic SMCs the effect is thought to be predominantly via the 
P2Y2R 37. Migration in response to UTP involves both P2Y2 and P2Y4 receptors 40.  The 
migratory capacity of extracellular nucleotides could be mediated by inducing the 
expression of extracellular matrix (ECM) proteins such as osteopontin, an RGD 
containing ECM protein 61,68. UTP-induced osteopontin expression involves the 
transcription factors NFκB and USF-1/USF2 75. The role of nucleotides as a 
chemoattractant is consistent with the concentration range found in pathological vessels 
76. Moreover, findings from previous studies demonstrating the mitogenic activity of 
extracellular nucleotides for SMCs suggest that nucleotides released from mechanically-
 13
stimulated or damaged cells during the angioplasty process may participate in arterial 
wall remodeling 69.  
Phenotypic Modulation of P2Y2R  
Experimental arterial intimal hyperplasia can be evoked by balloon angioplasty, 
or by the perivascular placement of a silicone collar around an artery 69. An influx of 
leukocytes precedes the migration and proliferation of vascular SMCs into the intima in 
both of these models 77. P2Y2R mRNA is expressed at low levels in endothelial cells and 
a few medial smooth muscle cells under normal conditions. In arteries, P2Y2R expression 
was increased by balloon angioplasty or collar placement 42,68. This increase in P2Y2R 
expression is also correlated with three phases of neointimal hyperplasia in the collar 
model 78. The first phase characterized by vascular infiltration of leukocytes begins 2 h 
after the collar is placed around a rabbit carotid artery 78. The second phase characterized 
by medial replication of SMCs begins within 12 h after collar placement  78. The third 
phase is characterized by the appearance of sub-endothelial SMCs which begins at day 3 
after collar placement 78. The appearance of P2Y2R mRNA was detected within 3 days of 
collar placement in SMCs and by day 14 was detected in all intimal and medial smooth 
muscle cells 68. In the same experiments, levels of P2Y4 receptor mRNA did not change 
and P2Y6 receptor mRNA was not detected. Similar observations of P2Y2R upregulation 
have been made in the porcine coronary artery stent model 73. A role for P2Y2Rs in 
atherosclerosis is further suggested by the demonstration of P2Y2Rs in the basilar artery 
of a rat double-hemorrhage model 79, in coronary arteries of a diabetic dyslipidemic pig 
model 80 and in human atherosclerotic lesions (Seye and Desgranges, unpublished data).  
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Pathophysiological Significance of Phenotypic Modulation of P2 Receptors in 
Smooth Muscle Cells  
The shift in the phenotypic status of SMCs from a differentiated contractile 
phenotype to a synthetic phenotype has been suggested to be related to an increase in the 
level of P2 receptor expression 37. In the synthetic phenotype, the mitogenic P2Y1 and 
P2Y2 receptor transcripts were upregulated, while the contractile P2X1 receptor was 
completely downregulated and P2Y4 and P2Y6 receptor levels were unchanged 81. Data 
indicate that the P2Y2R is expressed at a high level in medial SMCs of injured rat aorta 
42, thus linking it to the poorly differentiated phenotype, a condition  similar to that in the 
post-natal phase of development, where SMCs are confined to the medial layer and are in 
the immature state 82. The increased P2Y2R levels may be required for the modulation of 
proliferation or vasoreactivity of SMCs by nucleotides 69. Since both neointimal 
hyperplasia and vasoconstrictive remodeling are involved in postangioplastic restenosis, 
these findings suggest that extracellular nucleotides might play a significant role in this 
process, at least as long as functional endothelial cells, which control intimal thickening 
and nucleotide-induced vasorelaxation, are not regenerated 69. SMC P2Y2 receptors are 
involved in nucleotide-induced constriction of normal arteries 83,84. Long-lasting 
alterations in vasomotricity after endothelial denudation results in increased sensitivity to 
vasoconstrictive substances 85,86. It appears that similar to other receptors of 
vasoconstrictive factors such as angiotensin II, endothelin, and platelet-derived growth 
factor (PDGF) that are overexpressed in neointima, nucleotides acting through P2Y2 
receptors may play an important role in controlling the vasoactive properties of arteries 
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under pathophysiological conditions, particularly with chronic constriction at the lesion 
site that may lead to postangioplastic restenosis 69. 
VII. Potential Factors Involved in P2Y2 Receptor Upregulation. 
            Several factors have been shown to regulate P2Y2R upregulation. Shear stress 
induces upregulation of P2Y2Rs in human blood vessels with intact endothelium 87. In rat 
smooth muscle cells, fetal calf serum and growth factors upregulate P2Y2R mRNA 
expression by a MAP kinase kinase-dependent pathway 88. Using quantitative reverse 
transcription-polymerase chain reaction (RT-PCR), it was shown that phenotypic changes 
in vascular smooth muscle cells regulate P2 receptor expression 37. In rat salivary gland 
cells during short-term culture, a time-dependent increase in P2Y2R activity occurs that is 
associated with an increase in the steady-state level of P2Y2R mRNA, as assessed by RT-
PCR 89. P2Y2R mRNA upregulation also occurs as an immediate early gene response in 
T cell differentiation 90, in collared rabbit carotid arteries 68, in response to  stab wound 
injury in astrocytes 91, and in submandibular gland (SMG) cells from the NOD.B10 
mouse model of Sjögren’s syndrome as compared to wild type mouse SMG cells  92. 
            Among the prime candidates for factors that can cause upregulation of human 
P2Y2R expression are cytokines, growth factors and shear stress. Positioning a silicone 
collar around the carotid artery of rabbits induces vascular injury possibly due to 
hindrance of transmural blood flow, leading to retention of cytokines/growth factors 
within the segment enclosed by the collar 77.  
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Cytokines and Growth Factors 
           Previous studies have reported that cytokines such as tumor necrosis factor-α 
(TNF-α) in combination with interleukin 1-β (IL-1β), and IL-1β in combination with 
interferon-γ, induce P2Y2R upregulation in rat SMCs and increase mitogenic responses to 
nucleotides 81. In SMCs and other cell types, upregulation of P2Y2Rs has been associated 
with stimulation of PKC, cyclooxygenase, and MAP kinases 88,93.  
TNF-α released from macrophages and T-lymphocytes, injured human coronary 
artery endothelial cells and activated SMCs is one of the most important promoters of 
inflammation 94.  TNF-α induces activation of major signaling pathways involved in the 
activation of endothelial cells (i.e., the IκB kinase/nuclear factor κB [IKK/NF-κB] 
pathway) 94. It is possible that NF-κB elements in the P2Y2R 5’-flanking region may be 
involved in the transcriptional regulation of P2Y2R expression.  
Laminar and Shear Stress 
Certain flow-sensitive proteins are regulated by the transcription factor Sp1. For 
example, Sp1 is involved in regulatory mechanisms of flow-sensitive proteins, such as 
endothelial Toll-like receptor 2 in human coronary artery endothelial cells 95 . It has also 
been shown that fluid shear stress-induced transcriptional activation of the VEGF 
receptor-2 gene and Flk-1/KDR (fetal liver kinase-1) requires Sp1-dependent DNA 
binding  96,97. The presence of Sp1 and EGR1 (early growth response-1) binding sites 
immediately upstream and close to the putative transcription start sites of the P2Y2R gene 
indicates that these sites could potentially be involved in the regulation of P2Y2R 
transcription (Figure 2). 
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           Vascular stress conditions including ischemia/oxidative stress, vascular flow, and 
mechanical stretch are known to cause increased release of nucleotides 98,99. Shear stress 
affects endothelial structure and function, both in vivo and in vitro, and is implicated as a 
contributing factor in the development of cardiovascular diseases 100,101. Endothelial cells, 
because of their unique localization at the blood/blood vessel wall interface, are 
constantly exposed to fluid mechanical forces, such as shear stress derived from flowing 
blood. A shear stress response element in the PDGF A-chain promoter was described that 
contains a binding site for the transcription factors EGR1/Sp1 102.  
Other Inflammatory Mediators 
Lipopolysaccharide (LPS) has been shown to cause vascular endothelial growth 
factor (VEGF) upregulation via activation of Sp-1 103. LPS has been shown to be 
involved in the upregulation of P2Y2Rs in rat SMCs 104.  
Phenotypic Changes  
In the synthetic phenotype of SMCs, mitogenic P2Y1 and P2Y2 transcripts were 
upregulated by 342- and 8-fold, respectively, while the contractile P2X1 receptor was 
completely downregulated and expression levels of P2Y4 and P2Y6 receptors were 
unchanged 37. This plasticity of P2 receptor expression may be important in the transition 
from the contractile to the synthetic SMC phenotype. 
Thus, many factors at the site of injury could cause upregulation of P2Y2Rs. By 
studying the P2Y2R promoter, we aim to find the cis and trans acting factors involved in 
P2Y2R expression. Furthermore, we hope to delineate the signaling pathway involved in 
P2Y2R upregulation.  
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VIII. Eukaryotic Promoters And Prediction of Regulatory Elements 
Eukaryotic promoters are DNA sequences that regulate gene expression at the 
level of transcription. These promoters have a complex block-modular structure and 
contain numerous short functional elements, i.e., transcription factor binding sites 105. The 
distal elements have no uniform location, are dispersed in the 5’-flanking region up to ~ 1 
kb upstream of the transcription start site (TSS), and are involved in specific 
transcriptional regulation of gene expression (e.g., tissue- and cell-specific regulation, 
etc.) 106. The proximal elements, which encompass the TSS, are called core promoters 
and are involved in formation of the basal transcription complex  106. 
Core Promoters 
The narrow region around the TSS has been considered to be important for 
understanding promoter functionality 107 and this region is termed the “core promoter”. 
Core promoters are also considered to control basal transcription 105. The core promoter 
region 105,107-109 can be defined as the minimal continuous segment of DNA sufficient for 
accurate initiation and directionality of transcription. However, the definition is 
ambiguous regarding the length of the region covered by the core promoter. In most 
cases, promoter elements considered important for the functionality of the core promoter 
region can be spread over the segment -60 to +50 bp relative to the TSS 110,  and thus it 
makes sense to consider this segment as representing the core promoter.  An often 
overlooked component of the core promoter is its active participation in the regulation of 
eukaryotic gene expression.  The core promoter is actually the ultimate target of all 
transcription factors and co-regulators that control the transcriptional activity of every 
gene  109. 
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The common elements belonging to the basal transcription complex are: 
1) A TATA box with consensus sequence TATA(A/T)A(A/T), the first eukaryotic 
core promoter motif to be identified  111,112.  
2) Inr with the consensus sequence of YYA+1N(T/A)YY 113,114 or 
TCA+1(G/T)T(C/T) in Drosophila 115-117. 
3) A subset of TATA boxes possesses an upstream sequence termed the BRE, which 
is a recognition site for the binding of TFIIB 118. The consensus sequence for the 
BRE is (G/C)(G/C)(G/A)CGCC, where the 3’-C of the BRE is immediately 
followed by the 5’-T of the TATA box. 
4) DPE or downstream promoter element is a recognition site for TFIID and is    
conserved from Drosophila to humans 109. 
   Most promoters contain a combination of one or two of these basic core 
promoter elements and all of these elements are known to interact with each other.   
Transcription initiation begins with the formation of a basal transcription complex in 
the promoter region several dozen bp long located around the TSS 105. In turn, 
assembly of the basal transcription complex at TATA-containing promoters starts 
with the recognition of TATA boxes by the TATA-binding protein (TBP) 105. On 
average, the sequence -300 to -50 bp of the TSS positively contributes to core 
promoter activity 105. Interestingly, a large comprehensive study of promoter function 
showed the presence of putative negative elements around -1000 to -500 bp upstream 
of the TSS for 55% of genes tested 119. 
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IX. Cloning of the P2Y2 Receptor and Mapping of the Gene 
  P2Y2 receptors (P2Y2Rs) were previously known as P2U receptors, 73,120-122. The 
human P2Y2R gene has been mapped to 11q13.5-14.1 on chromosome 11 123. G protein-
coupled receptor genes for the β-adrenergic receptor, angiotensin receptor-like-1 and 
muscarinic cholinergic receptor-1 have also been localized to chromosome 11 124. 
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CHAPTER 2 : CHARACTERIZATION AND FUNCTIONAL ANALYSIS OF THE 
P2Y2 RECEPTOR GENE PROMOTER 
 
 
 
I. Introduction 
Atherosclerosis is a multi-factorial disease involving endothelial dysfunction and 
is thought to be initiated by vascular injury. Extracellular nucleotides that are released 
from a variety of arterial and blood cells can bind to the P2Y2 receptor (P2Y2R) and 
modulate proliferation and migration of smooth muscle cells, which is known to be 
involved in intimal hyperplasia that accompanies atherosclerosis and post-angioplasty 
restenosis. A direct pathological role is reinforced by recent evidence showing that 
activation of the P2Y2R mediates intimal hyperplasia 68. Moreover, the P2Y2R is 
upregulated in vascular smooth muscle cells and endothelial cells in response to tissue 
injury 42. These findings also suggest that the P2Y2R is a potential target for the 
pharmacological control of the progression of atherosclerosis and post-angioplasty 
restenosis. However, despite the potential role of the P2Y2R in the atherogenic process, 
the mechanisms governing P2Y2R upregulation remain unknown.  
In this study, we have initiated attempts to investigate the human P2Y2R gene 
promoter by cloning its 5’-flanking region into pGL3, a luciferase reporter vector, 
followed by transfection in human coronary artery endothelial cells and SH-SY5Y 
neuroblastoma cells. A serial deletion analysis of a 2071 bp 5’-flanking region in SH-
SY5Y neuroblastoma cells showed that interspersed positive and negative response 
elements might be involved in the regulation of the P2Y2R gene. Moreover, the deletion 
of a 175 bp region including exon1 and a 41 bp immediate upstream region completely 
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abolished promoter function showing that the core promoter is located in this region. 
These results indicate that the P2Y2R gene promoter is a GC rich promoter with multiple 
transcription start sites and uses an array of positive and negative response elements in 
the regulation of gene expression. Furthermore, other experiments indicate that the 
cytokine IL-1β may be involved in downregulation of P2Y2R expression in human 
coronary artery endothelial cells. Further studies are needed to identify specific cis and 
trans acting factors involved in the regulation of P2Y2R gene expression. This study will 
potentially lead to the identification of novel pathways involved in the regulation of 
P2Y2R gene expression, information that might be useful to suppress neointimal 
hyperplasia in atherosclerosis and restenosis after angioplasty.  
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II. Materials and Methods: 
Vectors  
 pGL3-basic vector and SV40 promoter pGL3 vector were obtained from 
Promega  (Madison, WI, USA). CMV-pGL3, which has the CMV promoter cloned in the 
basic pGL3 vector, was a gift from David Pintel (Department of Microbiology and 
Molecular Immunology, University of Missouri-Columbia, USA). 
RNA Isolation 
              PolyA+ RNA was isolated from total RNA of human coronary artery endothelial 
cells (HCAECs). The Oligotex kit from Qiagen (Valencia, CA, USA) was used for 
PolyA+ mRNA isolation and total RNA was isolated using the RNeasy Midi kit from 
Qiagen, according to the manufacturer’s instructions. Total RNA obtained from 1 
confluent T-75 flask of HCAECs was around 7-15 µg.  The concentration and purity was 
determined by measuring absorption at 260 nm and 280 nm. A 260/280 ratio of 1.8 – 2.0 
was considered to indicate relatively pure RNA. Five µg of total RNA or 0.1 µg of 
PolyA+ RNA was used for the primer extension reaction.  
Primer Extension Reaction 
             Single-stranded 43-mer anti-sense oligonucleotide (10 pmol) (5’-
CTCTCGCCACTGCGCTGCGCTTCTCCTCTCAGGGTGCCGTCGC-3’), 
(Tm=75.3ºC) corresponding to exon1 in the P2Y2R gene sequence was designed and 
chemically synthesized, end-labeled using polynucleotide kinase from Promega 
(Madison, WI, USA) and  [γ-32P]-adenosine 5`-triphosphate from Perkin Elmer (Boston, 
MA, USA); EasyTides® adenosine 5`-triphosphate, 250 µCi (9.25 MBq), specific 
activity: 3000 Ci (111 TBq)/mMole). Labeled primers (1 pmol) were used for 
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hybridization with 5 µg of polyA+ RNA. The primer was annealed with the mRNA at 5 
ºC below it’s melting temperature (Tm) for 20 min. After annealing, the reaction was 
maintained at room temperature for 10 min. AMV reverse transcriptase was added for 30 
min at 41 ºC to yield the corresponding cDNA. Sample Buffer from the Promega kit was 
added and AMV reverse transcriptase was inactivated by incubating all samples at 90 ºC 
for 10 min. The products were then analyzed on a 8% (w/v) polyacrylamide denaturing  
gel. Then, 1.2 kb kanamycin-positive mRNA from the Promega kit was used with a 
control primer as a positive control. The negative control included diethylpyrocarbonate- 
(DEPC-) treated water instead of mRNA in the reaction.    
PCR Amplification of the Putative P2Y2R Gene Promoter Region from Genomic 
DNA 
           Using genomic DNA obtained from Promega as template, the 5’-flanking region 
of the P2Y2R gene was amplified. The primers designed  were Mlu-2071 (5-
CGGACGCGTGGCAGGAGGACTGCTTGGACTCAGC-3’) and Xho-134 (5’-
CCGCTCGAGCTCTCGCCACTGCGCTGCGC-3’) and were PAGE purified by IDT 
(Coralville, IA, USA), which amplified a 2071 bp 5’-flanking region including the region 
encoding the first exon of P2Y2R as reported for the mRNA variants 1 and 2 with 
accession IDs of NM_176072 and NM_002564, respectively (NCBI). Primers Mlu-4620 
and Xho-134 were used to amplify a 5380 bp fragment, the longest variant with respect to 
the 5’-end. The primers selected were between 24-30 nucleotides long with an annealing 
temperature of 68-72 oC. The following PCR parameters were used in preliminary studies 
to yield a product on a 0.8% (w/v) agarose gel stained with ethidium bromide: pre-
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amplification denaturation at 94 oC for 1 min, followed by 35-40 cycles of denaturation at 
94  oC for 1 min, annealing at 66 oC for 1 min and elongation at 68 oC for 6 min.   
Construction of the Initial Promoter Reporter Construct 
The above generated fragments were digested using MluI and XhoI and ligated to the 
pGL3 vector digested with the same enzymes. The construct obtained was labeled as 
pNJ2071, transformed into JM109 competent cells and positive clones were identified by 
restriction enzyme digestion and confirmed by sequencing using RVprimer3 (5´-
CTAGCAAAATAGGCTGTCCC-3´) and GLprimer2 (5´- 
CTTTATGTTTTTGGCGTCTTCCA-3´) (Promega, Madison, WI). The pGL3 vector has 
multiple cloning sites just upstream and downstream of the inserted promoter in the 
following order: KpnI, SacI, MluI, NheI, SmaI, XhoI, Bgl II, and Hind III.  
Serial Deletion of the Promoter from the 5’ End 
To delineate the boundaries of the minimal functional promoter and regulatory 
elements within the 5’-flanking region of the P2Y2R gene, a series of 5’ serial deletions 
of the initial promoter-reporter (luciferase) construct were made using the Erase-a-base 
system from Promega (Madison, WI, USA) based on the method of Henikoff 125 and 
were transiently expressed in HCAECs and the luciferase activities of the reporter 
construct were measured. The pNJ2071 construct contains a 2071 bp upstream region 
cloned at the MluI and XhoI sites. This construct was first digested using Mlu I and Kpn 
I. This digestion provided a linear construct of approximately 6960 bp that has a 5’-
overhang at the Mlu I end of the construct and has a 3’-overhang at the Kpn I end. 
Exonuclease III was used to digest the 5’-overhang using the Erase-a-base kit from 
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Promega. A time-dependent reaction at 37 oC was used to obtain a linear construct that 
had deletions of various sizes as shown in Figure 4.  
Transient Transfections 
SH-SY5Y neuroblastoma cells were obtained from ATCC, and cultured using 
Dulbecco’s Modified Eagles’s Medium (DMEM)  supplemented with 10% FBS , L-
glutamate and non-essential amino-acids. SH-SY5Y neuroblastoma cells were plated in 
24 well plates for 24 h in antibiotic-free medium. SH-SY5Y cells were seeded in 24 well 
plates and transfected at 70-80% confluence. Transient transfections were performed 
using Lipofectamine 2000 with 1.92 pmoles of each of the 6 serially deleted constructs 
(Table 3) and pNJ-1937/-41. To compensate for the different amounts of DNA arising 
due to size differences of the various deletion constructs, equal concentrations of the 
plasmid DNA were used by adding non-interfering DNA (pBLUESCRIPT SK-) with 
each of the serial deletions. Renilla luciferase driven by thymidine kinase (pHRLTK) 
from Promega (Madison, WI, USA) was used as an internal control and co-transfected 
with each of the deletion constructs.  
Human coronary artery endothelial cells were obtained from Cambrex and were 
maintained in EGM-2 medium. Transfection was done by electroporation using 
Nucleofector Reagent from Amaxa Biosystem (Gaithersburg, MD, USA).  The cells were 
first dispersed by trypsinization, as described in the manual for HCAEC Nucleofector 
Reagent (VPB-1001) then collected and resuspended in Nucleofector Reagent. At least 5 
µg of DNA were used for transfection of 5 X 105 cells.  
Plasmids for transfection  were prepared and purified using a Maxiprep kit 
purchased from Macherey-Nagel (Easton, PA, USA).  
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Table 3 : Concentrations of plasmid DNA used in transfection of SHSY-5Y 
neuroblastoma cells 
Promoter 
Construct 
Plasmid Size    
(bp) pmol 
Amount. of 
DNA (µg) 
Filler 
(µg) 
pHRGTK (µg) 
(0.192 pmol) 
pNJ-1937/+134 6889 0.384 1.72 0 0.12 
pNJ-1678/+134 6630 0.384 1.66 0.06 0.12 
pNJ-1320/+134 6272 0.384 1.564 0.156 0.12 
pNJ-1086/+134 6038 0.384 1.504 0.216 0.12 
pNJ-692/+134 5644 0.384 1.406 0.314 0.12 
pNJ-266/+134 5218 0.384 1.3  0.42 0.12 
pNJ-235/+134 5187 0.384 1.292 0.428 0.12 
pNJ-1937/-41 6714 0.384 1.67  0.05 0.12 
pGL3basic 4818 0.384 1.2  0.52 0.12 
SV40pGL3 5010 0.384 1.248 0.472 0.12 
CMVpGL3 5611 0.384 1.397 0.329 0.12 
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Dual Luciferase Reporter Assay System 
          The various promoter reporter constructs obtained from deletions and mutations as 
described above were transfected into human SH-SY5Y neuroblastoma cells using 
Lipofectamine 2000. The concentrations of each maxiprep DNA (Nucleobond Plasmid 
Maxi Kit-Macherey Nagel) (Easton, PA, USA) were estimated using 1:10 dilution and 
calculated using the Nanodrop method (NanoDrop® ND-1000 Spectrophotometer) 
(Wilmington, DE, USA). After 24 h, cells were washed with phosphate buffered saline 
and lysed with passive lysis buffer  as described in  the dual luciferase reporter system 
manual (E1910) from Promega (Madison, WI, USA).  Ten µl of the lysate supernatant 
were analysed for luciferase (LUC) reporter activity on a single tube luminometer  
(Turner Biosystems, Sunnyvale, CA, USA) using the dual luciferase reporter system. The 
transfection efficacy was normalized by a luciferase internal control vector pHRL-TK 
from Promega (Madison, WI, USA).  A minimum of triplicate experiments were carried 
out.  A ratio of 2:1 of experimental vector:internal control vector was used for each of 
these experiments. For the cytokine stimulation experiments, after 16-24 h, cells were 
treated with cytokines for another 24 h, washed with phosphate buffered saline and lysed 
with passive lysis buffer.  The luciferase activity for each sample was calculated as a ratio 
of experimental divided by the renilla luciferase activity. These values were then used to 
calculated the Percentage relative response ratio (RRR) as follows. The positive control 
used was SV40-pGL3 and negative control used was basic-pGL3. 
 
Percentage RRR =  (experimental sample ratio) – (negative control ratio)     X  100 
(positive control ratio) – (negative control ratio) 
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III. Results and Discussion: 
1) Genomic Organization of the P2Y2R Gene 
              The three reference sequences (Refseqs) for P2Y2R mRNA that are shown below 
were obtained from cDNA libraries from human renal cell carcinoma, airway epithelium 
and adult blood leukocytes as indicated in Figure 1. The diagrammatic representation below 
shows the exon-intron structure of P2Y2R as derived by schematic computational analysis 
126. The similarity in the color indicates the similarity in the sequence between the three 
mRNA transcripts. The P2Y2R is proposed to encode at least three mRNA variants each of 
which have three exonic and two intronic regions. The coding sequence is intronless and the 
three variants differ in the 5’-untranslated region (UTR).  
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Figure 1: P2Y2R gene organization  
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Figure 1: P2Y2R gene structure and organization 
P2Y2R transcripts from the NCBI (National Center for Biotechnology Information) 
Database – Refseqs. Color scheme is modified such that the regions with similar sequences 
have the same color.  
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2a) Cloning of the P2Y2R Gene 5’-upstream Sequence 
The 2.071 kb upstream of the ATG start codon was cloned into the pGL3 Basic 
luciferase reporter plasmid to generate the plasmid pNJ-2071/+134 and the sequence was 
analyzed by the Proscan computer program 127. A consensus TATA box was not found in 
the 2.071 kb region analyzed. Furthermore, in the same sequence, a CpG island was 
predicted when CpG island-finding software (CpG Finder, Softberry) (Softberry Inc., 
Mount Kisco, NY, USA) was used. The CpG island was 274 bp long in a region spanning 
exon 1 of these transcripts with a P(CpG)/exp score of 0.895 (threshold is 0.6). This score 
represents the Min gc_ratio = P(CpG)/(expected)P(CpG) and is defined as the minimal 
ratio of the observed to expected frequency of CpG dinucleotide in the island The 
percentage of CG content was found to be 75.9%. This information is consistent with 
vertebrate genomes that contain CpG islands in regions about 1-2 kilobases in length 
where the dinucleotide CpG is present at the expected frequency and in an unmethylated 
form 128. The location of these CpG islands is almost always coincident with the 5’-end of 
genes, often overlapping the first exon. 129 . It is estimated that 56% of all human genes 
are associated with CpG islands 128. The unmethylated status in some cases is dependent 
on binding of the transcription factor Sp1 130. We also found putative binding sites for 
Sp1 within the same region (Figure 2). The region being analyzed is thus a likely 
candidate for analysis of the P2Y2R gene promoter.  
Reference website for the software used:  
http://softberry.com/berry.phtml?topic=cpgfinder&group=programs&subgroup=promoter 
Results presented as raw output below: 
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Search parameters:  
Length of the CpG island: >= 100    
% GC: 50.0    
P(CpG)/exp: 0.600    
Output is as follows:  
Found: 1 CpG Island 
Start:   1     
end:    32    
chain: +   
CpG:   13  
% CG:  75.0       
CG/GC: 0.812        
P(CpG)/exp:     0.973(0.98)                      
P(CpG):  0.131       
Length of the CpG island :     274  
2b) Promoters Predicted by the Promoter Predicting Programs (PPPs) Identified 
the Region for Experimental Verification 
Promoter Predicting Programs (PPPs) are important in silico tools for guiding 
experimental biologists. Once the approximate putative regions for promoters have been 
detected using PPPs, reporter gene assays based on a series of deletion mutants can be 
used to further narrow down the DNA regions that play the most important role in the 
promoter activities 131. The information on transcription factor binding sites predicted by 
the commonly available and non-commercial softwares (TESS, University of 
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Pennsylvania; Matinspector 2.0, Genomatix Software GmbH, Germany) was assimilated 
and the most relevant sites are presented in Figure 2.  
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Figure 2: Putative binding sites in the immediate 5’-flanking region of the P2Y2R 
gene 
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Figure 2: Putative binding sites in the immediate 5’-flanking region of the P2Y2R 
gene: Putative Transcription factor binding sites are indicated by underlined sequences. 
The green region represents 134 bp of exon 1 and the region in yellow represents a 31 bp 
sequence deleted in pNJ-235/+134. 
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3) Determination of Transcription Start Site(s) by Primer Extension Analysis 
We used primer extension analysis to identify the probable transcription initiation 
site(s) in the P2Y2R gene with mRNA extracted from HCAECs. The single-stranded 43-
mer oligonucleotide used was highly specific for P2Y2R mRNA exon 1. The expected 
cDNA product size was 134 bp if the transcription start site for P2Y2R mRNA conformed 
to mRNA transcripts arrived at for P2Y2R mRNA by in silico analysis 126, as shown in 
Figure 1. The positive control was a 1.2 kb kanamycin-positive in vitro product that was 
expected to give a product size of 84 bp. The chief cDNA products obtained by primer 
extension were smaller (57 bp and 84 bp) and larger (200 bp) than predicted (Figure 3). 
More than one transcription start site has been known to be associated with TATAless 
promoters 132. However, formation of products due to secondary structures in mRNA in 
the primer extension reaction cannot be ruled out. Further experiments such as 5’-RACE 
(Rapid Amplification of cDNA ends) analysis and RNAse protection assays need to be 
done to confirm the transcription start sites.  
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Figure 3: Determination of transcription start site(s) by primer extension analysis. 
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Figure 3. Determination of transcription start site(s) by primer extension analysis. 
Primer extension analysis revealed one major transcription start site in extracts of mRNA 
from human coronary artery endothelial cells (H) and some weak intensity products of 
sizes from 100-230 bp. A positive control (C) from the Promega kit was included that 
produced a band at 84 bp. Hinf I digested markers (M) were used as standards to compare 
the sizes of the products.  
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4) Deletion Analysis of the Promoter from the 5’-end  
In initial studies, we tested the pNJ-1937/+134 construct for promoter activity in 
cell lines previously reported to show endogenous P2Y2R expression, such as HCAECs 
and human salivary gland (HSG) cells. To define the mechanisms controlling 
transcriptional regulation of P2Y2R in HCAECs, a series of deletion constructs (Figure 4) 
were generated and transiently transfected in SH-SY5Y neuroblastoma cells.  
Deletion mutant pNJ-1678/+134 exhibited a drastic decrease in reporter activity 
as shown by a decrease in percentage of relative response ratio (RRR) (percentage of 
RRR is calculated as relative increases for pGL3 expressed as a percentage of SV40 
promoter-driven luciferase activity as described in ‘methods’ section) by 119% (Figure 
4). Deletion mutant pNJ-1320/+134 exhibited slightly greater reporter activity (Figure 4). 
Deletion mutant pNJ-1086/+134 showed luciferase activity similar to the pNJ-1678/+134 
mutant (Figure 4).  The pNJ-692/+134 mutant exhibited some reporter activity, similar to 
the pNJ-1320/+134 mutant (Figure 5). Thus, the 5’-flanking region showed interspersed 
positive and negative regulatory elements. Furthermore, the pNJ-266/+134 mutant 
showed similar reporter activity to pNJ-1937/+134, which was further dramatically 
increased for deletion mutant pNJ-235/+134 (Figure 4). Analysis of this 31 bp sequence 
showed putative binding sites for C/EBPβ (CCAAT enhancer binding protein), WHN 
(winged helix nude), E2F, and MyT1 (myelin transcription factor 1) zinc finger 
transcription factors known to act as repressors of transcription activity of other genes 133-
135.  Moreover, the analysis of luciferase reporter activity for the deletion mutant pNJ-
1937/-41 revealed a complete loss of activity, especially when compared to the full-
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length construct pNJ-1937/+134 and pNJ-235/+134 (Figure 4). Analysis of this region 
revealed multiple putative sites for Sp1 and a putative site for EGR1.  
We analyzed the similarity of the putative C/EBPβ binding sequence to the 
consensus binding sequence of C/EBP 136, and according to TESS this sequence was 
graded as a good match.  C/EBPβ belongs to a family of transcription factors composed 
of at least five distinct members known to be associated with the regulation of cell 
growth and differentiation 136. It is thought that C/EBPβ has a possible role in the brain, 
since it is known that C/EBPβ mRNA is widely expressed in adult mouse brain 136. 
Constitutive expression of C/EBPβ is particularly high in liver, intestine, lung, adipose 
tissue, spleen, kidney and myelomonocytic cells 136. C/EBPβ protein is widely distributed 
in the brain of post-natal rats when the dendritic arbor of neurons develops  137. C/EBPβ 
overexpression significantly increases programmed cell death, probably through a 
mechanism involving the cell cycle-dependent proteins p53 and p21 136. C/EBPβ might 
play an important role in the regulation of neuronal differentiation and cell death 138. We 
postulate that C/EBPβ is one of the factors involved in the repression of P2Y2R gene 
expression, as shown by the increase in luciferase activity with deletion mutant pNJ-
235/+134 (Figure 4). The role of the P2Y2R in the nervous system is less well 
understood, but it has been shown that P2Y2Rs can couple to neuronal ion channels 139, 
can activate nerve growth factor/TrkA signaling 140,  and can modulate pain responses  
141.  It has been suggested that P2Y2Rs and their associated signaling pathways may be 
important factors regulating astrogliosis in brain disorders 142. 
Combining the data from the primer extension analysis and the deletion analysis, 
it can be concluded that the region between -41 to +134 plays an important role in the 
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initiation of P2Y2R transcription. This region might represent the core promoter of the 
P2Y2R gene and may be responsible for conferring basal transcriptional activity.  This 
can be concluded because pNJ-1937/-41 has all the regulatory elements that are present 
in other constructs except the region that has been deleted from -41 to +134. Furthermore, 
the P2Y2R flanking region shows interesting putative cis-regulatory elements that should 
be mutated further to determine their involvement in the transcriptional regulation of 
P2Y2R expression.  More conclusive information on transcription factors involved in 
P2Y2R gene expression can be obtained by site-directed mutagenesis of specific 
transcription factor binding sites, as shown in Table 4. Furthermore, gel mobility shift 
assays and chromatin immunoprecipitation assays can be carried out with wild type and 
mutated constructs to confirm the involvement of these putative transcription factor 
binding sites.  
 
 
 
 
 
 
 
 
 
 
 
 43
 
 
Figure 4: Luciferase activity of the promoter deletion constructs 
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Figure 4.  Luciferase activity of the promoter deletion constructs: A- Serial deletions 
of the pNJ2071 (pNJ-1937/+134) construct. B- Luciferase activities of the deletion 
plasmids transfected into SH-SY5Y cells. Values corrected to the promoterless plasmid 
reporter activity are expressed as a percentage of control SV40 promoter-driven reporter 
activity and represent the mean ±S.E. of results from at least three experiments.  
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5) Effect of IL-1β on the Luciferase Reporter Activity Driven by the 2071 Bp 5’-
flanking Region  
In rat smooth muscle cells, it is known that interleukin (IL)-1ß induces a time- and 
dose-dependent upregulation of P2Y2 receptor mRNA, which was dramatically enhanced 
when combined with interferon-γ or tumor necrosis factor-α 104. We wanted to see if IL-
1-1β can induce upregulation of the promoter driven reporter activity in human coronary 
artery endothelial cells. To analyze this effect, human coronary artery endothelial cells 
were transfected with the full-length construct pNJ2071 followed by stimulation with IL-
1β at 50 ng/ml for 24 h, and luciferase activities were determined as shown in Figure 5. 
This indicates that at this particular IL-1β concentration and at this particular time 
interval, IL-1β decreased promoter activity by 20%. It is possible that certain repressors 
in the 5’-flanking region of P2Y2R could be involved in the IL-1β-induced decrease in 
promoter activity. Similar experiments in SH-SY5Y cells also indicated either no 
response or a slight decrease in luciferase activity induced by IL-1β. Future experiments 
should include transfection of human coronary artery endothelial cells by several serial 
deletion mutants to test the effects of IL-1β and the effect of a concentration dose 
response of IL-1β. These experiments may indicate the elements involved in IL-1β 
induced downregulation of P2Y2R promoter activity. It is possible that in human 
coronary artery endothelial cells IL-1β has an opposite effect, but this needs to be further 
confirmed using other quantitative approaches at the endogenous mRNA level. IL-1β is 
known to be involved in the repression of  the transcription of cartilage-derived retinoic 
acid-sensitive protein (CD-RAP) via C/EBPβ 133 in rat chondrocytes. Interestingly, the 
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deletion analysis has indicated that there might be a functional C/EBPβ binding element 
in the P2Y2R putative promoter region (Figures 2 and 4). 
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Figure 5: Effect of IL-1β on luciferase reporter activity for the 2071 bp 5'-flanking 
region of P2Y2R expressed in human coronary artery endothelial cells. 
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Figure 5. Effect of IL-1β on luciferase reporter activity for the 2071 bp 5'-flanking 
region of P2Y2R expressed in human coronary artery endothelial cells. Stimulation 
of HCAEC transfectants with 50 ng/ml IL-1β for 24 h showed that the 5’-flanking region 
of P2Y2R (prom) exhibits a slight negative regulation in response to IL-1β.  
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IV. Summary 
Several cis-regulatory elements are present in the 5’-flanking region of P2Y2R 
that was analyzed. Deletion analysis indicates that certain elements and/or interaction 
between elements present between 235 bp upstream and 2071 bp upstream of the putative 
transcription initiation site might be important for repression of P2Y2R gene expression 
in SH-SY5Y cells.  In particular, the sequence between deletion 5 and deletion 6 (pNJ-
235/+134) showed the presence of putative binding sites for C/EBP and WHN, which 
have been shown to be involved in repression of other genes  133,143. The data from the 
primer extension analysis indicates the presence of multiple transcription initiation sites 
in the immediate (within approximately 60 - 70 bp) P2Y2R 5’-flanking region as well as 
some strong initiation sites within exon1. Moreover, we found that the ability of this 
putative promoter region to drive luciferase reporter gene expression was completely lost 
when the region between -46 and +134 bp was deleted. These results indicate the 
presence of transcription initiation sites in the region between -46 to +134 bp. 
Furthermore, stimulation experiments indicated that IL-1β might be involved in 
downregulation of  P2Y2R activity in human coronary artery endothelial cells.  Taken 
together, these findings suggest the presence of a GC rich promoter for P2Y2R that 
utilizes an array of interspersed positive and negative regulatory elements that might be 
involved in sequence-specific and signal-specific stimulation of P2Y2R gene expression. 
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Table 4 : Putative transcription factor binding sites in the 5’-flanking region of 
P2Y2R gene 
(as present in the respective construct) 144,145  
 
pNJ -235/+134 
 
Family/matrix Further 
Information 
Opt. Position Str. Core 
sim. 
Matrix 
sim. 
Sequence 
(red: ci-value > 60 
capitals: core 
sequence) 
V$MAZF/MAZR.01 MYC-
associated 
zinc finger 
protein 
related 
transcription 
factor 
0.88 -26/-38 (-) 1.000 0.916 gggggcGGGGcgg 
V$RARF/RAR.02 Retinoic acid 
receptor, 
member of 
nuclear 
receptors, 
DR5 site 
0.70 -28/-56 (+) 0.960 0.702 ccagGGTCagtcaaaagtccgcccc
gccc 
V$SP1F/SP1.01 Stimulating 
protein 1, 
ubiquitous 
zinc finger 
transcription 
factor 
0.88 -29/-43 (-) 1.000 0.913 ggcgGGGCggacttt 
V$WHZF/WHN.01 Winged helix 
protein, 
involved in 
hair 
keratinization 
and thymus 
epithelium 
differentiation 
0.95 -101/-
111 
(-) 1.000 0.950 gggACGCcgcc 
V$SP1F/SP1.02 Stimulating 
protein 1, 
ubiquitous 
zinc finger 
transcription 
factor 
0.85 -102/-
116 
(+) 1.000 0.914 cgctGGGCggcgtcc 
V$MYBL/VMYB.02 v-Myb 0.90 -152/-
164 
(-) 1.000 0.958 tgcAACGggaggg 
V$SP1F/SP1.02 Stimulating 
protein 1, 
ubiquitous 
zinc finger 
transcription 
factor 
0.85 -163/-
177 
(-) 1.000 0.863 ggtcGGGCggcgacg 
V$WHZF/WHN.01 Winged helix 
protein, 
involved in 
hair 
0.95 -172/-
182 
(-) 1.000 0.985 gcgACGCtctc 
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keratinization 
and thymus 
epithelium 
differentiation 
 
         
 
           pNJ -235/+134  to pNJ-266/+134 
 
V$E2FF/E2F.02 E2F, involved in cell cycle 
regulation, interacts with Rb 
p107 protein 
0.84 -
251/-
261 
(-
) 
1.000 0.886 agagacgcCAAAgtttt 
V$WHZF/WHN.01 Winged helix protein, 
involved in hair 
keratinization and thymus 
epithelium differentiation 
0.95 -
252/-
262 
(-
) 
1.000 0.953 gagACGCcaaa 
V$MYT1/MYT1.02 MyT1 zinc finger 
transcription factor involved 
in primary neurogenesis 
0.88 -
258/-
270 
(-
) 
1.000 0.993 ccaAAGTtttgcc 
 
          
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 52
APPENDIX 
Future Work and Directions 
Preliminary deletion analysis studies with HCAEC transfectants indicated very 
different results than obtained with SH-SY5Y cell transfectants. These results need to be 
confirmed by repeated analysis. These results suggest that negative regulation is the 
hallmark for P2Y2R expression using transient transfection approaches. This is consistent 
with Dr. Seye’s earlier work showing that the P2Y2R is normally expressed at low levels 
in rabbit carotid arteries 68. 
Futhermore, to precisely define the regions of the promoter necessary for P2Y2R 
basal expression in HCAECs, serial site-directed mutagenesis of the core promoter 
should be performed. Mutant promoter constructs can be created in pGL3 basic vector, 
each containing 10 consecutive mutated bases, and expressed in HCAECs and other cell 
types for assay of luciferase activity.   
The results obtained by the luciferase assays for the deletion constructs 
transfected in SH-SY5Y cells should be confirmed using real time PCR or competitive 
RT-PCR assays.  
We have already generated some constructs to begin ribonuclease protection 
assays for the confirmation of the transcription start site(s) of P2Y2R that were indicated 
by the primer extension analysis.  
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